Company description

Bio-Bridge Science, Inc. (ticker symbol BBIO) is a biotechnology company that focuses on developing and commercializing innovative medicines for patients with rare and serious diseases. The company was founded in 2011 and is headquartered in Bellevue, Washington. BBIO's main focus is on developing treatments for genetic conditions, with a particular interest in gene-modifying therapies that can potentially cure patients. Their pipeline includes a variety of multi-gene disorders, such as Duchenne muscular dystrophy and Friedreich’s ataxia. In addition to their innovative pipeline, BBIO also has a robust research and development program, leveraging cutting-edge technologies and partnerships to advance the development of new therapies. The company has a global presence, with operations and collaborations in North America, Europe, and Asia. BBIO prides itself on its patient-centered approach, aiming to improve the lives of patients and their families by providing much-needed treatments. With a strong and dedicated team, a solid pipeline, and a patient-driven focus, BBIO is poised to continue making significant contributions to the field of biotechnology and improving the lives of those affected by rare and serious diseases.